NCT06003244

High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)

Effect of Supplemental Oxygen Therapy (SOT) in Patients With Pulmonary Vascular Diseases (PVD) Defined as Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension (PH) Who Permanently Live >2500m on 6-minute Walk Distance (6MWD)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: University of Zurich · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The investigators aim to study the effect of SOT in participants with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live \>2500m on 6-minute walk distance (6MWD) assessed at 2840m.

Detailed description

Participants with PVD diagnosed with precapillary PH with right heart catheterization and classified to groups 1 and 4 (PAH or CTEPH) who permanently live at HA \>2500 (PVDHA) will have 6-minute walk distance near their living altitude in Quito at 2840m with and without SOT at 3l/min via nasal cannula according to a randomized cross-over design.

Conditions

• Pulmonary Vascular Disease
• Pulmonary Artery Hypertension
• Chronic Thromboembolic Pulmonary Hypertension

Interventions

Type	Name	Description
OTHER	6-minute walk distance (6MWD) test	6-minute walk distance (6MWD) test will be performed according to clinical standards
OTHER	6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)	6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (3l/min, nasal)

Timeline

• Start date: 2023-09-23
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2023-08-21
• Last updated: 2023-10-05

Locations

1 site across 1 country: Switzerland